Ziyadeh assumed his current CEO position in February 2023. In December 2024, Julphar announced a $80 million investment to establish a state-of-the-art biopharmaceutical plant in Saudi Arabia. In 2025, it signed a partnership with South Korea’s Dong-A ST to introduce innovative biotechnology products to the region and launched a locally manufactured portfolio of modern Insulin Analogue. It has planned investment of $81.7 million to develop cutting-edge manufacturing lines in the U.A.E. and broaden its export reach to over 35 countries globally.